SequelSEC

ORAMED PHARMACEUTICALS INC. ORMP

Pharmaceutical Preparations · CIK 0001176309 · Fiscal year ends 1231

Revenue
$2.00M
Fiscal year ended 2025-12-31
Operating income
-$15.09M
Fiscal year ended 2025-12-31
Free cash flow
-$9.15M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$77.66MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.92Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income1.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue38.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin3202.5%100th
Gross margin0.6%7th
SBC / revenue299.6%81th
CapEx / revenue0.4%28th
Current ratio6.98x70th
FCF margin-457.7%34th
Operating margin-754.4%37th
R&D / revenue319.0%57th
Effective tax rate15.0%47th

ORAMED PHARMACEUTICALS INC. (ORMP) reported revenue of $2.00M and net income of $64.05M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ORAMED PHARMACEUTICALS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ORAMED PHARMACEUTICALS INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$2.00M
Cost of revenue$1.99M
Gross profit$13.00K
Operating income-$15.09M
Net income$64.05M
Research & development$6.38M
Weighted-average diluted sharesUnavailable
Pretax income$75.32M
Income tax expense$11.31M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$8.72M
Selling & marketingUnavailable

Balance

ORAMED PHARMACEUTICALS INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$45.95M
Total assets$230.86M
Current assets$133.27M
Total liabilitiesUnavailable
Current liabilities$19.09M
Total equity incl. NCI$199.74M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$443.00K

Cash flow

ORAMED PHARMACEUTICALS INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$9.14M
Capital expenditures$9.00K
Investing cash flow$5.44M
Financing cash flowUnavailable
Net change in cash-$8.47M
Stock-based compensation$5.99M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

ORAMED PHARMACEUTICALS INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flow-$9.15M
Gross margin0.6%
Operating margin-754.4%
FCF margin-457.7%
SBC / revenue299.6%
Current ratio6.98x
Revenue YoY growthUnavailable
Net margin3202.5%
R&D / revenue319.0%
CapEx / revenue0.4%
Long-term debt / equityUnavailable
Effective tax rate15.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ORMP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-19View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.